Marshall Wace LLP Sells 420,262 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Marshall Wace LLP reduced its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 90.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,861 shares of the company's stock after selling 420,262 shares during the quarter. Marshall Wace LLP's holdings in 10x Genomics were worth $673,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. FMR LLC raised its stake in shares of 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock valued at $193,206,000 after acquiring an additional 86,455 shares during the last quarter. ARK Investment Management LLC increased its holdings in 10x Genomics by 11.1% during the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after purchasing an additional 1,193,712 shares during the period. Assenagon Asset Management S.A. bought a new position in 10x Genomics during the 4th quarter valued at approximately $26,308,000. Barclays PLC lifted its holdings in 10x Genomics by 31.3% in the 4th quarter. Barclays PLC now owns 790,957 shares of the company's stock worth $11,357,000 after buying an additional 188,421 shares during the period. Finally, Trexquant Investment LP grew its position in shares of 10x Genomics by 196.2% in the 4th quarter. Trexquant Investment LP now owns 594,611 shares of the company's stock worth $8,539,000 after buying an additional 393,854 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Stifel Nicolaus decreased their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 13th. UBS Group cut their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Barclays decreased their price target on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, Citigroup cut their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of "Hold" and an average price target of $18.85.

10x Genomics Trading Down 4.8 %

NASDAQ:TXG traded down $0.42 during trading hours on Tuesday, reaching $8.20. 1,940,026 shares of the company traded hands, compared to its average volume of 2,265,058. The business's 50-day moving average price is $9.10 and its two-hundred day moving average price is $12.73. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $28.25. The stock has a market capitalization of $1.00 billion, a P/E ratio of -5.39 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan Mateo bought 40,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was bought at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. The trade was a 184.41 % increase in their position. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.